Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

234P - Germline mutations in index patients with ductal carcinoma in situ (DCIS): A single center retrospective study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Kaissa Ouali

Citation

Annals of Oncology (2020) 31 (suppl_4): S303-S339. 10.1016/annonc/annonc267

Authors

K. Ouali1, B. Verret2, D. Wehrer1, V. Goldbarg1, A. Larive3, M. Joulia1, S. Villebasse1, M. Di Maria1, S. Delaloge2, O. Caron1

Author affiliations

  • 1 Clinical Genetic Unit, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 2 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 Statistics Unit, Gustave Roussy Institute, 94800 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 234P

Background

While the referral criteria are established in suspicion of genetic predisposition to invasive breast cancer (IBC), there are currently no guidelines on genetic testing for breast ductal carcinoma in situ (DCIS). A few papers described a 3.2 to 29.2% BRCA1 and BRCA2 pathogenic variants (PV) yield in DCIS. Moreover, little is known about the subsequent IBC risk in PV carriers.

Methods

Since 2000, DCIS has been considered equivalent to IBC as a referral criterium for genetic testing in our center. Women with pure DCIS who have been referred to our genetic clinic between 01/01/2000 and 31/12/2019 and who underwent germline testing for breast cancer genes as an index case (including at least BRCA1 and BRCA2) were included in the present analysis. Exclusion criteria included personal history of other malignancy. We collected clinical characteristics and outcomes from medical files.

Results

Out of 9736 female index cases who underwent germline breast cancer predisposing genes testing over the period, 178 had pure DCIS. Of them, 5 (2,8%) and 11 (6,2%) had a PV in BRCA1 or BRCA2, respectively. TP53 and PALB2 VP rates were 5,2% (4/59) and 2,5% of tested women (2/79). Medium age at diagnosis was significantly lower in patients with a PV than those without (41,9 versus 47 years (p=0,042). Family history of ovarian cancer, but not of breast cancer, in first or second degree relatives, was associated with identification of a PV (p<0,01 and p=0,16, respectively). Pathological characteristics of DCIS were not associated with the probability of PV. Prophylactic contralateral mastectomy was performed in 43% of the PV carriers and only in 3,2% of cases in the WT group.

Conclusions

In our study, applying IBC genetic testing criteria to DCIS was effective with a 12% VP yield, but, interestingly, family history of breast cancer did not seem predictive of VP identification. No histological feature was associated with identification of a PV.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.